NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT01443065 2020-11-17
MEGA
UNICANCER
Phase 2 Completed
NCT02926638 2020-03-19
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network
Phase 2/3 Terminated
NCT01039207 2017-09-07
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT01233687 2017-06-22
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
University of Pittsburgh
Phase 1/2 Completed
NCT01791374 2016-02-29
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Amgen
Phase 1 Completed
NCT01697072 2016-02-09
RILOMET-1
Amgen
Phase 3 Terminated
NCT01113398 2015-12-10
AMG 102 and Avastin for Recurrent Malignant Glioma
Duke University
Phase 2 Completed
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT01105390 2013-08-02
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Withdrawn